This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Aug;7(8):416.

doi: 10.1038/nrurol.2010.111.

Prostate cancer: Degarelix controls serum alkaline phosphatase better than leuprolide

PMID: 20726066
DOI: 10.1038/nrurol.2010.111

Comment

Prostate cancer: Degarelix controls serum alkaline phosphatase better than leuprolide

Nick Warde. Nat Rev Urol. 2010 Aug.

. 2010 Aug;7(8):416.

doi: 10.1038/nrurol.2010.111.

Author

PMID: 20726066
DOI: 10.1038/nrurol.2010.111

No abstract available

PubMed Disclaimer

Comment on

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE. Schröder FH, et al. BJU Int. 2010 Jul;106(2):182-7. doi: 10.1111/j.1464-410X.2009.08981.x. Epub 2009 Nov 13. BJU Int. 2010. PMID: 19912212 Clinical Trial.

References

1. BJU Int. 2010 Jul;106(2):182-7 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.